visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment |
Data: | 2023 |
Resum: | In the clinical course of Alzheimer's disease (AD) development, the dementia phase is commonly preceded by a prodromal AD phase, which is mainly characterized by reaching the highest levels of Aβ and p-tau-mediated neuronal injury and a mild cognitive impairment (MCI) clinical status. Because of that, most AD cases are diagnosed when neuronal damage is already established and irreversible. Therefore, a differential diagnosis of MCI causes in these prodromal stages is one of the greatest challenges for clinicians. Blood biomarkers are emerging as desirable tools for pre-screening purposes, but the current results are still being analyzed and much more data is needed to be implemented in clinical practice. Because of that, plasma extracellular vesicles (pEVs) are gaining popularity as a new source of biomarkers for the early stages of AD development. To identify an exosome proteomics signature linked to prodromal AD, we performed a cross-sectional study in a cohort of early-onset MCI (EOMCI) patients in which 184 biomarkers were measured in pEVs, cerebrospinal fluid (CSF), and plasma samples using multiplex PEA technology of Olink© proteomics. The obtained results showed that proteins measured in pEVs from EOMCI patients with established amyloidosis correlated with CSF p-tau181 levels, brain ventricle volume changes, brain hyperintensities, and MMSE scores. In addition, the correlations of pEVs proteins with different parameters distinguished between EOMCI Aβ( +) and Aβ(-) patients, whereas the CSF or plasma proteome did not. In conclusion, our findings suggest that pEVs may be able to provide information regarding the initial amyloidotic changes of AD. Circulating exosomes may acquire a pathological protein signature of AD before raw plasma, becoming potential biomarkers for identifying subjects at the earliest stages of AD development. |
Ajuts: | Ministerio de Ciencia e Innovación FJC2018-036012-I Ministerio de Ciencia e Innovación PID2021-122473OA-I00 Ministerio de Ciencia e Innovación PID2021-123462OB-I00 Agencia Estatal de Investigación PID2019-106625RB-I00 Instituto de Salud Carlos III CD22/00125 Instituto de Salud Carlos III FI20/00215 Instituto de Salud Carlos III PI17/01474 Instituto de Salud Carlos III PI19/00335 Instituto de Salud Carlos III PI22/01403 Instituto de Salud Carlos III PI22/00258 Instituto de Salud Carlos III CB06/05/2004 Instituto de Salud Carlos III CB18/05/00010 European Commission 115975 |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Matèria: | Plasma exosomes ; Extracellular vesicles ; Cerebrospinal fluid ; Proteomics ; Alzheimer's disease ; Mild cognitive impairment |
Publicat a: | Journal of nanobiotechnology, Vol. 21 (February 2023) , art. 54, ISSN 1477-3155 |
19 p, 5.2 MB |